JP2021525236A5 - - Google Patents
Info
- Publication number
- JP2021525236A5 JP2021525236A5 JP2020564482A JP2020564482A JP2021525236A5 JP 2021525236 A5 JP2021525236 A5 JP 2021525236A5 JP 2020564482 A JP2020564482 A JP 2020564482A JP 2020564482 A JP2020564482 A JP 2020564482A JP 2021525236 A5 JP2021525236 A5 JP 2021525236A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- acid sequence
- antibody
- pharmaceutical composition
- Prior art date
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862673426P | 2018-05-18 | 2018-05-18 | |
| US62/673,426 | 2018-05-18 | ||
| PCT/IB2019/054104 WO2019220412A2 (en) | 2018-05-18 | 2019-05-17 | Safe and effective method of treating lupus with anti-il12/il23 antibody |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2021525236A JP2021525236A (ja) | 2021-09-24 |
| JP2021525236A5 true JP2021525236A5 (https=) | 2022-05-25 |
| JPWO2019220412A5 JPWO2019220412A5 (https=) | 2022-05-25 |
| JP7421500B2 JP7421500B2 (ja) | 2024-01-24 |
Family
ID=68532802
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020564482A Active JP7421500B2 (ja) | 2018-05-18 | 2019-05-17 | 抗ｉｌ１２／ｉｌ２３抗体でループスを治療する安全かつ有効な方法 |
Country Status (4)
| Country | Link |
|---|---|
| US (2) | US11578124B2 (https=) |
| EP (1) | EP3793521A4 (https=) |
| JP (1) | JP7421500B2 (https=) |
| WO (1) | WO2019220412A2 (https=) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018119142A1 (en) | 2016-12-21 | 2018-06-28 | Amgen Inc. | Anti-tnf alpha antibody formulations |
| US20200197517A1 (en) * | 2018-12-18 | 2020-06-25 | Janssen Biotech, Inc. | Safe and Effective Method of Treating Lupus with Anti-IL12/IL23 Antibody |
| AU2020386669A1 (en) * | 2019-11-19 | 2022-06-02 | Novartis Ag | Methods of treating Lupus Nephritis using interleukin-17 (IL-17) antagonists |
| CN113035299B (zh) * | 2021-04-02 | 2022-03-29 | 上海药明津石医药科技有限公司 | 分中心推荐方法、装置、计算机设备和存储介质 |
| WO2023057369A2 (en) * | 2021-10-04 | 2023-04-13 | Astrazeneca Ab | Treatment of lupus |
| WO2024100139A1 (en) * | 2022-11-09 | 2024-05-16 | Merck Patent Gmbh | Use of ifn-i activity as a biomarker for tlr inhibitor treatment |
| WO2024102200A1 (en) * | 2022-11-10 | 2024-05-16 | Ampel Biosolutions, Llc | Methods and systems for evaluation of lupus based on ancestry-associated molecular pathways |
| WO2024129960A2 (en) * | 2022-12-16 | 2024-06-20 | Vetmab Biosciences, Inc. | Anti-il23 and anti-tnfα antibodies: compositions and veterinary use |
| AU2024301395A1 (en) * | 2023-07-21 | 2025-12-11 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Use of il-12 related biomarkers and il-12 specific blocking antibodies for the treatment of an autoimmune disease |
| WO2025143577A1 (ko) * | 2023-12-28 | 2025-07-03 | 아주대학교 산학협력단 | 전신 홍반성 루푸스 플레어 예측용 바이오마커 |
| US12494266B1 (en) * | 2024-06-10 | 2025-12-09 | Recursion Pharmaceuticals, Inc. | Utilizing a clinical-phenomics causal discovery framework to generate causal discovery predictions |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5457038A (en) | 1988-11-10 | 1995-10-10 | Genetics Institute, Inc. | Natural killer stimulatory factor |
| US5811523A (en) | 1988-11-10 | 1998-09-22 | Trinchieri; Giorgio | Antibodies to natural killer stimulatory factor |
| CA2441636A1 (en) | 1988-11-10 | 1990-05-10 | The Wistar Institute Of Anatomy And Biology | Natural killer stimulatory factor |
| US6683046B1 (en) | 1989-12-22 | 2004-01-27 | Hoffmann-La Roche Inc. | Purification and characterization of cytotoxic lymphocyte maturation factor and monoclonal antibodies thereto |
| ATE366311T1 (de) | 1989-12-22 | 2007-07-15 | Hoffmann La Roche | Zytotoxischer lymphozyten-reifefaktor 35kd untereinheit und monoklonale antikörper spezifisch dafür |
| DE4315127A1 (de) | 1993-05-07 | 1994-11-10 | Behringwerke Ag | Arzneimittel enthaltend die Untereinheit p40 von Interleukin-12 |
| CA2125763C (en) | 1993-07-02 | 2007-08-28 | Maurice Kent Gately | P40 homodimer of interleukin-12 |
| ZA95960B (en) | 1994-03-14 | 1995-10-10 | Genetics Inst | Use of interleukin-12 antagonists in the treatment of autoimmune diseases |
| WO1995029239A2 (en) | 1994-04-22 | 1995-11-02 | Corixa Corporation | Compounds and methods for the stimulation and enhancement of protective immune responses and il-12 production |
| US5891680A (en) | 1995-02-08 | 1999-04-06 | Whitehead Institute For Biomedical Research | Bioactive fusion proteins comprising the p35 and p40 subunits of IL-12 |
| CA2219361C (en) | 1995-04-27 | 2012-02-28 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US5853697A (en) | 1995-10-25 | 1998-12-29 | The United States Of America, As Represented By The Department Of Health & Human Services | Methods of treating established colitis using antibodies against IL-12 |
| AU6150498A (en) | 1997-02-07 | 1998-08-26 | Wistar Institute, The | Methods and compositions for the inhibition of interleukin-12 production |
| US6060284A (en) | 1997-07-25 | 2000-05-09 | Schering Corporation | DNA encoding interleukin-B30 |
| WO1999037682A2 (en) | 1998-01-23 | 1999-07-29 | F.Hoffmann-La Roche Ag | Antibodies against human il-12 |
| JP3579355B2 (ja) | 1998-12-09 | 2004-10-20 | プロテイン デザイン ラブス インコーポレイティド | ヒトの乾癬を予防及び治療するための乾癬モデル動物 |
| SI2168984T1 (sl) | 1999-03-25 | 2012-12-31 | Abbott Gmbh & Co. Kg | Človeška protitelesa za vezavo IL-12 in postopki izdelave |
| US6914128B1 (en) | 1999-03-25 | 2005-07-05 | Abbott Gmbh & Co. Kg | Human antibodies that bind human IL-12 and methods for producing |
| AU7127600A (en) | 1999-09-17 | 2001-04-17 | Basf Aktiengesellschaft | Methods and compositions for modulating responsiveness to corticosteroids |
| US6902734B2 (en) | 2000-08-07 | 2005-06-07 | Centocor, Inc. | Anti-IL-12 antibodies and compositions thereof |
| US20160279239A1 (en) * | 2011-05-02 | 2016-09-29 | Immunomedics, Inc. | Subcutaneous administration of anti-cd74 antibody for systemic lupus erythematosus and autoimmune disease |
| SG158150A1 (en) | 2004-12-21 | 2010-01-29 | Centocor Inc | Anti-il-12 antibodies, epitopes, compositions, methods and uses |
| US20070238094A1 (en) * | 2005-12-09 | 2007-10-11 | Baylor Research Institute | Diagnosis, prognosis and monitoring of disease progression of systemic lupus erythematosus through blood leukocyte microarray analysis |
| EP2205276A4 (en) | 2007-09-28 | 2012-08-15 | Janssen Biotech Inc | ANTI-IL-12 / 23P40 ANTIBODIES, EPITOPES, FORMULATIONS, COMPOSITIONS, METHODS AND USES |
| CA2819538A1 (en) * | 2010-11-30 | 2012-06-07 | Vereniging Voor Christelijk Hoger Onderwijs, Wetenschappelijk Onderzoek En Patientenzorg | Method for prognosticating the clinical response of a patient to b-lymphocyte inhibiting or depleting therapy in interferon driven diseases such as sle. |
| EP2729174A1 (en) * | 2011-07-08 | 2014-05-14 | Merck Sharp & Dohme Corp. | Il-23 antagonists for treatment or prevention of skin rash associated with treatment with p13k/akt pathway inhibitors |
| ES2729603T3 (es) | 2012-06-27 | 2019-11-05 | Merck Sharp & Dohme | Anticuerpos IL-23 antihumanos cristalinos |
| US9809854B2 (en) * | 2012-11-15 | 2017-11-07 | New York Society For The Ruptured And Crippled Maintaining The Hospital For Special Surgery | Biomarkers for disease activity and clinical manifestations systemic lupus erythematosus |
| US20170002060A1 (en) | 2014-01-08 | 2017-01-05 | Moderna Therapeutics, Inc. | Polynucleotides for the in vivo production of antibodies |
| EP3143399A1 (en) * | 2014-05-12 | 2017-03-22 | Biogen MA Inc. | Biomarkers predictive of lupus progression and uses thereof |
| US11643460B2 (en) | 2014-10-28 | 2023-05-09 | Staley Brod | Administration of an anti-interleukin 12/23 antibody for treatment of autoimmune disease |
| JP6909208B2 (ja) * | 2015-09-17 | 2021-07-28 | アムジェン インコーポレイテッド | Ｉｌ２３経路バイオマーカーを使用するｉｌ２３アンタゴニストに対する臨床応答の予測 |
| US20170121417A1 (en) | 2015-11-03 | 2017-05-04 | Janssen Biotech, Inc. | Subcutaneous Formulations of Anti-CD38 Antibodies and Their Uses |
| AU2017241776B2 (en) | 2016-03-29 | 2024-06-20 | Janssen Biotech, Inc. | Treating psoriasis with increased interval dosing of anti-IL12 and/or -23 antibody |
| MA45122A (fr) | 2016-05-24 | 2019-04-10 | Constellation Pharmaceuticals Inc | Inhibiteurs hétérocycliques de cbp/ep300 et leur utilisation dans le traitement du cancer |
| TW201922780A (zh) | 2017-09-25 | 2019-06-16 | 美商健生生物科技公司 | 以抗ｉｌ１２／ｉｌ２３抗體治療狼瘡之安全且有效之方法 |
-
2019
- 2019-05-17 EP EP19804426.5A patent/EP3793521A4/en not_active Withdrawn
- 2019-05-17 US US16/415,231 patent/US11578124B2/en active Active
- 2019-05-17 WO PCT/IB2019/054104 patent/WO2019220412A2/en not_active Ceased
- 2019-05-17 JP JP2020564482A patent/JP7421500B2/ja active Active
-
2023
- 2023-01-13 US US18/154,116 patent/US20230279097A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021525236A5 (https=) | ||
| US11045546B1 (en) | Methods of treating coronavirus infection | |
| US20170121771A1 (en) | Interferon alpha-induced pharmacodynamic markers and uses thereof | |
| AU2008247398B2 (en) | Interferon alpha-induced pharmacodynamic markers | |
| JP2018008951A (ja) | インターフェロンγに対する抗体を使用した治療方法 | |
| Lopes et al. | Temporal profiling of cytokine-induced genes in pancreatic β-cells by meta-analysis and network inference | |
| JP2015524793A (ja) | 炎症阻害用の抗ｃｘｃｌ９、抗ｃｘｃｌ１０、抗ｃｘｃｌ１１、抗ｃｘｃｌ１３、抗ｃｘｃｒ３、及び抗ｃｘｃｒ５作用剤 | |
| JP2021525236A (ja) | 抗ｉｌ１２／ｉｌ２３抗体でループスを治療する安全かつ有効な方法 | |
| Park et al. | Interleukin 13–and interleukin 17A–induced pulmonary hypertension phenotype due to inhalation of antigen and fine particles from air pollution | |
| CN103732251A (zh) | 用针对干扰素-α的抗体治疗全身性红斑狼疮、硬皮病以及肌炎的方法 | |
| JP2019519475A (ja) | ヒト化抗ｃｌｅｖｅｒ−１抗体およびその使用 | |
| US20230374124A1 (en) | Compositions for treatment alopecia areata, biomarkers for treatment success and, methods of use thereof | |
| CN113692287A (zh) | I型干扰素标记及使用方法 | |
| TW202239767A (zh) | 用於治療類風濕性關節炎之組成物及方法 | |
| JPWO2019220412A5 (https=) | ||
| CN114025796A (zh) | 用抗il23特异性抗体治疗银屑病关节炎的安全且有效的方法 | |
| US20100261172A1 (en) | Interferon alpha-induced pharmacodynamic markers | |
| CA3214379A1 (en) | Treatments for prurigo nodularis | |
| JP2008515819A (ja) | 乾癬の予防及び治療用ｉ型インターフェロンブロッキング剤 | |
| JP2025134820A (ja) | Ｈｔｌｖ－１関連脊髄症（ｈａｍ）治療又は予防剤、及びｈａｍの治療方法 | |
| WO2019183437A1 (en) | Methods and compositions for antibody to high affinity receptor for ige | |
| JPWO2021113702A5 (https=) | ||
| US20260036592A1 (en) | DETECTION OF ANTI-VIRAL CDR3s IN CANCER | |
| JP2024542508A (ja) | 治療薬への応答に関連する多遺伝子スコアの層別化に基づく肺疾患の治療 | |
| Bills | Deletions in SARS-CoV-2 nsp6 enhance antagonism of type-I interferon signaling |